Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease

Understanding Aspergillus niger

At a Glance

An Aspergillus niger finding does not always mean infection: it may be contamination or colonization, especially in a respiratory sample. Symptoms, sample location, immune status, lung health, imaging, and specialized testing help determine whether treatment is needed.

Finding the word “Aspergillus” on a medical report can be alarming. Many people associate this fungus with serious lung infections, but the genus Aspergillus includes hundreds of different species that behave very differently [1]. Aspergillus niger (often called “black Aspergillus” or the “A. niger complex” in a laboratory setting due to its dark spores) is a common member of this group that is frequently found in the environment and on human skin or in the ear canal [2]. This color description does not mean it is the “toxic indoor mold” often discussed in the media, nor does a surface finding automatically prove disease.

While Aspergillus fumigatus is the leading cause of severe invasive disease, A. niger and other non-fumigatus species can still cause serious disease, and a surface or swab finding may represent contamination or colonization [1][2]. For many patients, the presence of A. niger requires careful context from your medical team.

Presence vs. Infection

One of the most important distinctions your doctor will make is whether the fungus is simply colonizing your body or causing an infection.

  • Colonization: This means the fungus is “just visiting” or living on a surface of your body (like the skin of the ear canal or inside a stable lung cavity) without invading your tissues or making you sick [3][4]. In many respiratory samples, Aspergillus is considered a colonizer and may not require treatment if you have no symptoms [4][5].
  • Infection: This occurs when the fungus begins to grow into your tissues or triggers an inflammatory response. This is usually accompanied by symptoms like pain, discharge, or a persistent cough [2][6].

Common Clinical Presentations

While A. fumigatus is famous for lung issues, A. niger is most commonly known for causing otomycosis, a superficial fungal infection of the outer ear canal [2][7].

Ear Infections (Otomycosis)

If A. niger was found in an ear swab, it is often linked to symptoms such as:

  • Intense itching (pruritus) [2].
  • Ear pain or a feeling of “fullness” [7].
  • Hearing loss or ringing in the ears (tinnitus) [7].
  • A wet, greyish, or black discharge [2].

Treatment for this is typically local, involving a thorough cleaning of the ear by a specialist (called aural toilet) and the use of antifungal ear drops [8][9]. Most patients recover fully with this approach [10].

Lung Findings

If A. niger appears in a respiratory sample (like sputum), doctors look for specific signs of disease before starting treatment. They may use a Chest CT scan to look for cavities or “fungal balls” (aspergillomas) [6][11]. While often less aggressive than A. fumigatus, A. niger can cause life-threatening, invasive lung infections, especially if a person has a severely weakened immune system, severe COPD, or critical illness [4][12].

The Challenge of “Cryptic Species”

Your report might say “Aspergillus niger,” but modern science has revealed that what looks like A. niger under a microscope might actually be one of several “cryptic species” [13][14]. These are species that are genetically different but look identical to the naked eye.

The most common of these is Aspergillus tubingensis [13]. This matters because different species can respond differently to medications:

  • A. tubingensis is more frequently found in lung samples than in ear samples [4][15].
  • A. tubingensis has shown variable in-vitro findings of reduced sensitivity to certain common antifungal drugs, like azoles, compared to a “true” A. niger [13][16].

Standard laboratory cultures often cannot tell these apart. However, every ear isolate or respiratory isolate does not require genetic confirmation. If your infection is invasive, refractory, or epidemiologically important, your doctor might request specialized testing, such as DNA sequencing or MALDI-TOF MS, to confirm exactly which species is present [17][14].

Understanding the Risk

For most healthy people, the risk of A. niger becoming an invasive infection is low [3]. However, doctors take it more seriously in specific high-risk groups, including:

  • People with very low white blood cell counts (neutropenia) [18].
  • Those taking high doses of steroids or other immunosuppressants [18].
  • Individuals with pre-existing, severe lung damage (like advanced COPD or old tuberculosis cavities) [6][11].

If you are generally healthy, a positive result for A. niger is often a signal for your doctor to check for a superficial issue (like an ear infection) or to monitor you, rather than an immediate medical emergency [4].

Common questions in this guide

Does finding Aspergillus niger mean I have an infection?
A positive result does not always mean you have an infection. The fungus may be a contaminant or may be colonizing a body surface without harming tissue, especially in a respiratory sample. Clinicians use the sample location, symptoms, immune status, imaging, and other tests to decide what it means.
What symptoms can Aspergillus niger cause in the ear?
A. niger can cause otomycosis, a fungal infection of the outer ear canal. Symptoms may include intense itching, pain, fullness, reduced hearing, ringing, or wet grayish or black discharge. Treatment often involves professional ear cleaning followed by antifungal ear drops.
Is Aspergillus niger in sputum always a lung infection?
No. Aspergillus in sputum can reflect colonization rather than tissue infection, so a result alone does not prove invasive disease. Doctors may consider symptoms, chest CT findings such as cavities or fungal balls, lung health, immune status, and additional tests before recommending treatment.
Who is most at risk for serious Aspergillus niger disease?
Risk is higher in people with very low white blood cell counts, high-dose steroid or other immunosuppressive treatment, severe lung damage such as advanced COPD or old tuberculosis cavities, or critical illness. For most otherwise healthy people, invasive infection is uncommon. A clinician should interpret risk based on the person's health and the location of the finding.
Why might a laboratory need more testing after reporting Aspergillus niger?
Some fungi that look like A. niger under a microscope are genetically different species, including Aspergillus tubingensis. Culture may not distinguish them, and species can differ in antifungal susceptibility. DNA sequencing or MALDI-TOF testing may be considered when disease is invasive, not responding to treatment, or important to investigate.
How is an Aspergillus niger infection treated?
Treatment depends on whether the finding is contamination, colonization, an outer-ear infection, or invasive disease. Ear infection is commonly managed with thorough ear cleaning and antifungal drops, while a respiratory finding may only be monitored if there is no evidence of disease. Suspected invasive infection requires prompt clinician-directed evaluation and antifungal treatment chosen for the specific situation.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Aspergillus niger infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific results and symptoms, is this 'colonization' (just present) or an 'infection' (causing harm)?
  2. 2.Was this identified as A. niger based on standard culture, or was it confirmed with more precise testing like MALDI-TOF or sequencing?
  3. 3.Does this finding change my current treatment plan or require new tests, like an ear examination or a chest CT?
  4. 4.If this is an infection, is the specific strain I have susceptible to standard antifungal medications?
  5. 5.If I have a respiratory result, should I have my Aspergillus-specific IgG or galactomannan levels checked?
  6. 6.What are the 'red flag' symptoms I should watch for that would suggest this is becoming more serious?

References

References (18)
  1. 1

    Diagnosis and Treatment of Invasive Aspergillosis Caused by Non-fumigatus Aspergillus spp.

    Stemler J, Többen C, Lass-Flörl C, et al.

    Journal of fungi (Basel, Switzerland) 2023; (9(4)) doi:10.3390/jof9040500.

    PMID: 37108955
  2. 2

    Otomycosis in iran: a review.

    Gharaghani M, Seifi Z, Zarei Mahmoudabadi A

    Mycopathologia 2015; (179(5-6)):415-24 doi:10.1007/s11046-015-9864-7.

    PMID: 25633436
  3. 3

    Non-fumigatus Aspergillus-associated pulmonary events: a diagnostic challenge.

    Godet C, Joste V, Frat J-P, et al.

    Journal of clinical microbiology 2026; (64(4)):e0016326 doi:10.1128/jcm.00163-26.

    PMID: 41848336
  4. 4

    Different repartition of the cryptic species of black aspergilli according to the anatomical sites in human infections, in a French University hospital.

    Gits-Muselli M, Hamane S, Verillaud B, et al.

    Medical mycology 2021; (59(10)):985-992 doi:10.1093/mmy/myab027.

    PMID: 34022772
  5. 5

    Clinical characteristics of patients with coronavirus disease 2019-associated pulmonary aspergillosis on mechanical ventilation: A single-center retrospective study in Japan.

    Ogawa Y, Murata K, Hasegawa K, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2023; (29(3)):239-243 doi:10.1016/j.jiac.2022.11.001.

    PMID: 36379404
  6. 6

    Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.

    Denning DW, Cadranel J, Beigelman-Aubry C, et al.

    The European respiratory journal 2016; (47(1)):45-68 doi:10.1183/13993003.00583-2015.

    PMID: 26699723
  7. 7

    Otomycosis in Southern China: a retrospective analysis of clinical presentation, otoendoscopic features, and causative pathogens.

    Wang Q, Xu D, Li Y, et al.

    Mycopathologia 2025; (191(1)):15 doi:10.1007/s11046-025-01036-3.

    PMID: 41452477
  8. 8

    Otomycosis in Africa: Epidemiology, diagnosis and treatment.

    Sangaré I, Amona FM, Ouedraogo RW, et al.

    Journal de mycologie medicale 2021; (31(2)):101115 doi:10.1016/j.mycmed.2021.101115.

    PMID: 33516991
  9. 9

    Aspergillus otitis externa: A retrospective study of predisposing factors, treatment, and complications.

    Viljanen M, Saarinen R, Hafrén L

    Laryngoscope investigative otolaryngology 2024; (9(5)):e70028 doi:10.1002/lio2.70028.

    PMID: 39464791
  10. 10

    Clinicopathological study of otomycosis in a tertiary hospital in South-west Nigeria.

    Sogebi OA, Oyewole EA, Osinupebi OA

    African health sciences 2024; (24(1)):69-75 doi:10.4314/ahs.v24i1.9.

    PMID: 38962337
  11. 11

    Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

    Denning DW, Rogers TR, Takazono T, et al.

    American journal of respiratory and critical care medicine 2026; doi:10.1093/ajrccm/aamag310.

    PMID: 42384914
  12. 12

    Characteristics of culture-positive invasive pulmonary aspergillosis in patients with hematologic diseases: Comparison between Aspergillus fumigatus and non-fumigatus Aspergillus species.

    Cho SY, Lee DG, Choi JK, et al.

    Medicine 2017; (96(49)):e8841 doi:10.1097/MD.0000000000008841.

    PMID: 29245249
  13. 13

    The accuracy and clinical impact of the morphological identification of Aspergillus species in the age of cryptic species: A single-centre study.

    Takeda K, Suzuki J, Watanabe A, et al.

    Mycoses 2022; (65(2)):164-170 doi:10.1111/myc.13397.

    PMID: 34783396
  14. 14

    Molecular Analysis for Potential Hospital-Acquired Infection Caused by Aspergillus Tubingensis Through the Environment.

    Tanamachi C, Iwahashi J, Togo A, et al.

    The Kurume medical journal 2024; (69(3.4)):185-193 doi:10.2739/kurumemedj.MS6934013.

    PMID: 38233176
  15. 15

    Isolated brain abscess caused by Aspergillus tubingensis in a patient with alcoholic liver cirrhosis.

    Inaba T, Minami K, Ishioka H, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2025; (31(5)):102691 doi:10.1016/j.jiac.2025.102691.

    PMID: 40164348
  16. 16

    Reduced Activity of Triazole Antifungal Agents Against Aspergillus tubingensis From a Global Collection of Genomically-Characterized Aspergillus Section Nigri Clinical Isolates (2020-2023).

    Kimbrough JH, Winkler ML, Karr MH, et al.

    Mycoses 2026; (69(7)):e70197 doi:10.1111/myc.70197.

    PMID: 42415524
  17. 17

    Black aspergilli: A remaining challenge in fungal taxonomy?

    D'hooge E, Becker P, Stubbe D, et al.

    Medical mycology 2019; (57(6)):773-780 doi:10.1093/mmy/myy124.

    PMID: 30535052
  18. 18

    Clinicomycological Study of the Spectrum of Pulmonary Aspergillosis at a Tertiary Care Hospital in Central India.

    Krishna A, Keche A, Tg R, Das P

    Cureus 2024; (16(3)):e56147 doi:10.7759/cureus.56147.

    PMID: 38618367

This page is for informational purposes only and does not constitute medical advice. Your clinician should interpret an Aspergillus niger result in light of your sample, symptoms, immune status, and other tests.